Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor

Journal of Clinical Oncology

Volumn 22, Issue 16, 2004, Pages 3357-3365

  Stewart, Clinton F ^b   Iacono, Lisa C ^b   Chintagumpala, Murali ^b   Kellie, Stewart J ^b   Ashley, David ^b   Zamboni, W C ^b   Kirstein, M N ^b   Fouladi, Maryam ^b   Seele, Louis G ^b   Wallace, Dana ^b   Houghton, Peter J ^b   Gajjar, Amar ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TARGETING; EXPERIENCE; HIGH RISK PATIENT; HUMAN; INFUSION; MEDICAL ASSESSMENT; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STANDARD; ADOLESCENT; ADULT; CEREBELLUM TUMOR; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; PATHOLOGY; PRESCHOOL CHILD; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BRAIN NEOPLASMS; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MEDULLOBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE; RISK FACTORS; TOPOTECAN; TREATMENT OUTCOME;

EID: 4344566362     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.103     Document Type: Article

References (43)

1. Packer RJ, Goldwein J, Nicholson HS, et al: Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 17:2127-2136, 1999
2. Tarbell N, Friedman H, Kepner JL: Outcome for children with high stage medulloblastoma: Results of the Pediatric Oncology Group 9031. Int J Radiat Oncol Biol Phys 48:179, 2000 (abstr 134)
3. Bailey CC, Gnekow A, Wellek S, et al: Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma: International Society of Pediatric Oncology (SIOP) and German Society of Paediatric Oncology (GPO) - SIOP II. Med Pediatr Oncol 25:166-178, 1995
4. Evans AE, Jenkin DT, Sposto R, et al: The treatment of medulloblastoma: Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72:572-582, 1990
5. Hughes EN, Shillito J, Sallan SE, et al: Medulloblastoma at the joint center for radiation therapy between 1968 and 1984: The influence of radiation dose on the patterns of failure and survival. Cancer 61:1992-1998, 1988
6. Tait DM, Thornton-Jones H, Bloom HJ, et al: Adjuvant chemotherapy for medulloblastoma: The first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 26:464-469, 1990
7. Kortmann RD, Kuhl J, Timmermann B, et al: Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46:269-279, 2000
8. Allen JC, Helson L: High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 55:749-756, 1981
9. Friedman HS, Mahaley MS Jr, Schold SC Jr, et al: Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma. Neurosurgery 18:335-340, 1986
10. Gaynon PS, Ettinger LJ, Baum ES, et al: Carboplatin in childhood brain tumors: A Children's Cancer Study Group Phase II trial. Cancer 66:2465-2469, 1990
11. Kovnar EH, Kellie SJ, Horowitz ME, et al: Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system. J Clin Oncol 8:330-336, 1990
12. Heideman RL, Kovnar EH, Kellie SJ, et al: Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors. J Clin Oncol 13:2247-2254, 1995
13. Taylor RE, Bailey CC, Robinson K, et al: Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 21:1581-1591, 2003
14. Friedman HS, Houghton PJ: Treatment of central nervous system xenografts with camptothecins. Ann N Y Acad Sci 803:210-212, 1996
15. Houghton PJ, Cheshire PJ, Hallman JD, et al: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393-403, 1995
16. Blaney SM, Cole DE, Balis FM, et al: Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 53:725-727, 1993
17. Baker SD, Heideman RL, Crom WR, et al: Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 37:195-202, 1996
18. Pawlik CA, Houghton PJ, Stewart CF, et al: Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays. Clin Cancer Res 4:1995-2002, 1998
19. Stewart CF, Liu CY, Zamboni WC, et al: Population pharmacokinetics of topotecan in children and adolescents. Proc Am Soc Clin Oncol 2000;19:177a (abstr 687)
20. Tubergen DG, Stewart CF, Pratt CB, et al: Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 18:352-361, 1996
21. Santana VM, Zamboni WC, Kirstein MN, et al: A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 9:633-640, 2003
22. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
23. Friedman HS, Oakes WJ, Bigner SH, et al: Medulloblastoma: Tumor biological and clinical perspectives. J Neurooncol 11:1-15, 1991
24. Zamboni WC, Gajjar AJ, Mandrell TD, et al: A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: Implications for treatment of children with metastatic medulloblastoma. Clin Cancer Res 4:2537-2544, 1998
25. Yeoh EJ, Cunningham JM, Yee GC, et al: Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells. Bone Marrow Transplant 28:563-571, 2001
26. Pratt CB, Stewart CF, Santana VM, et al: Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12:539-543, 1994
27. Zamboni WC, Stewart CF, Thompson J, et al: Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90:505-511, 1998
28. D'Argenio DZ, Schumitzky A: ADAPT II User's Guide (ed 1). Los Angeles, CA, Biomedical Simulations Resource, USC, 1990
29. Strother D, Ashley D, Kellie SJ, et al: Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: Results of a collaborative study. J Clin Oncol 19:2695-2704, 2001
30. Duffner P, Horowitz M, Krischer JP, et al: Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328:1725-1731, 1993
31. Blaney SM, Balis FM, Cole DE, et al: Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 53:1032-1036, 1993
32. Kadota RP, Stewart CF, Horn M, et al: Topotecan for the treatment of recurrent or progressive central nervous system tumors: A pediatric oncology group phase II study. J Neurooncol 43:43-47, 1999
33. Blaney SM, Needle MN, Gillespie A, et al: Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: A collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res 4:357-360, 1998
34. Nitschke R, Parkhurst J, Sullivan J, et al: Topotecan in pediatric patients with recurrent and progressive solid tumors: A Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 20:315-318, 1998
35. Pappo AS, Lyden E, Breneman J, et al: Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An intergroup rhabdomyosarcoma study. J Clin Oncol 19:213-219, 2001
36. Zamboni WC, Luftner DI, Egorin MJ, et al: The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid. Ann Oncol 12:119-122, 2001
37. Furman WL, Stewart CF, Kirstein M, et al: Protracted intermittent schedule of topotecan in children with refractory acute leukemia: A pediatric oncology group study. J Clin Oncol 20:1617-1624, 2002
38. Stewart CF, Zamboni WC, Crom WR, et al: Topoisomerase I interactive drugs in children with cancer. Invest New Drugs 14:37-47, 1996
39. Zamboni WC, Gajjar AJ, Heideman RL, et al: Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 4:783-789, 1998
40. Gajjar A, Kirstein MN, Santana VM, et al: Concomitant dexamethasone (DXM) increases topotecan (TPT) clearance in children. Proc Am Assoc Cancer Res 42:653, 2001 (abstr 3512)
41. Hale GA, Benaim E, Stewart CF, et al: A phase I study of cyclophosphamide and topotecan in patients with high risk malignancies undergoing autologous hematopoietic stem cell transplantation. Med Pediatr Oncol 37:175, 2001 (abstr O49)
42. Mastrangelo R, Lasorella A, Riccardi R, et al: Carboplatin in childhood medulloblastoma/PNET: Feasibility of an in vivo sensitivity test in an "up-front" study. Med Pediatr Oncol 24:188-196, 1995
43. Loeffler JS, Kretschmar CS, Sallan SE, et al: Pre-radiation chemotherapy for infants and poor prognosis children with medulloblastoma. Int J Radiat Oncol Biol Phys 15:177-181, 1988